Equillium, Inc.
EQ
Positions held
Your positionsEQ isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $91.31M | Enterprise value | $34.73M | Trailing P/E | — | Forward P/E | -6.15 |
| PEG | — | Price / book | 1.63 | Beta | 1.92 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -59.0% | ROA | -34.0% | Debt / equity | 0.01 |
| Current ratio | 23.40 | Free cash flow | -$14.30M | Analyst recommendation | strong_buy | Mean target | $8.56 |
| 52w high | $3.54 | 52w low | $0.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$4.7M | -$5.3M | -$3.8M | -$4.2M | -$5.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.2M | -$5.6M | -$4.0M | -$4.6M | -$6.2M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $41.1M | $36.1M | $15.8M | — |
| Op margin | — | -20.1% | -40.2% | -247.6% | — |
| Net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.6M | -$8.3M | -$14.5M | -$39.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
2026-10-05 · Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
2026-09-29 · Equillium Announces Poster Presentations at the 7th International AHR Conference
2026-09-27 · Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
2026-09-16 · Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
2026-09-02 · Equillium to Participate in Upcoming Investor Conferences
2026-08-20 · EQ Inc. Reports Second Quarter 2026 Financial Results
2026-08-13 · Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-07-21 · Integrated Rewards Expands Offer Network into Everyday Spend Categories Like Fuel, Hotel and Grocery
2026-07-13 · Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target
Price (daily)
Full chart · RSI · MACD · patterns